TargetBeta
IDH2
isocitrate dehydrogenase (NADP(+)) 2 · also IDH-2 · Isocitrate dehydrogenases
2 programs in company-led studies act on IDH2, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 124 running | IDH1 | NCIt |
| ranosidenibrule | HUTCHMED | phase 3 | 73 running | IDH1 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Astrocytoma, 2 programs
- Glioma, 2 programs
- Leukemia, Myeloid, Acute, 2 programs
- Cholangiocarcinoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 23, 2026vorasidenib · Agios Pharmaceuticals · phase 3 · NCT07250633
- Dec 2026ranosidenib · HUTCHMED · phase 3 · NCT07025018
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.